

2012 PHARMACEUTICALS RESEARCH REVIEW



PHM099C
December 2012

Various Analysts
Project Analyst

ISBN: 0-89336-482-7

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports: carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 FOREWORD	1
CHAPTER 2 GLOBAL MARKETS FOR TREATMENTS FOR SYNDROMES OF PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS (REPORT PHM118A)	3
INTRODUCTION	3
STUDY OBJECTIVES	3
REASONS FOR DOING THIS STUDY	3
CONTRIBUTIONS OF THE STUDY AND FOR WHOM	4
SCOPE OF THE STUDY	4
METHODOLOGY	4
INFORMATION SOURCES	4
ABOUT THE AUTHOR	4
RELATED BCC RESEARCH REPORTS	5
EXECUTIVE SUMMARY	5
<i>TABLE 1 GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, THROUGH 2017 (\$ MILLIONS)</i>	6
<i>FIGURE 1 GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010-2017 (\$ MILLIONS)</i>	6
OVERVIEW	6
DEFINITIONS	7
NEURONS	7
CENTRAL NERVOUS SYSTEM	7
BRAIN	7
SPINAL CORD	7
NEUROTRANSMITTERS	7
CLASSIFICATION	8
<i>TABLE 2 CLASSIFICATION BY PRIMARY DYSFUNCTION</i>	8
PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS	8
FRIEDREICH'S ATAXIA	8
GERSTMANN-STRAUSSLER-SCHEINKER DISEASE	9
MACHADO-JOSEPH DISEASE	9
AMYOTROPHIC LATERAL SCLEROSIS	9
HEREDITARY SPASTIC PARAPLEGIA	10
HEREDITARY NEUROPATHIES	10
MULTIPLE SCLEROSIS	10
DIAGNOSTIC TESTS FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS	11
DIAGNOSTIC TESTS FOR MULTIPLE SCLEROSIS	11
DIAGNOSTIC TESTS FOR AMYOTROPHIC LATERAL SCLEROSIS	11
DIAGNOSTIC TESTS FOR FRIEDREICH'S ATAXIA	11
DIAGNOSTIC TESTS FOR MACHADO-JOSEPH DISEASE	12
DIAGNOSTIC TESTS FOR HEREDITARY SPASTIC PARAPLEGIA	12
DIAGNOSTIC TESTS FOR HEREDITARY NEUROPATHIES	12
GLOBAL MARKETS	12
MARKETS BY DYSFUNCTION	12
MARKET OVERVIEW	13
MARKET REVENUE	13

TOPIC	PAGE NO.
<i>TABLE 3 GLOBAL REVENUES OF DRUG PRODUCTS FOR THE TREATMENT OF NEURODEGENERATIVE DYSFUNCTIONS, THROUGH 2017 (\$ MILLIONS)</i>	14
<i>FIGURE 2 GLOBAL REVENUES OF DRUG PRODUCT FOR THE TREATMENT OF NEURODEGENERATIVE DYSFUNCTIONS, 2010-2017 (\$ MILLIONS)</i>	14
MARKET SHARE	14
<i>TABLE 4 MARKET SHARE OF DRUGS USED FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS BY DYSFUNCTIONS, 2011 (%)</i>	15
<i>FIGURE 3 MARKET SHARE OF DRUG USED FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS BY DYSFUNCTION, 2011 (%)</i>	15
MARKETS BY DISORDERS	15
MARKET OVERVIEW	16
CURRENT SITUATION	17
MARKET TRENDS	17
PROGRESSIVE ATAXIAS SYNDROMES	17
Market Drivers	18
PROGRESSIVE WEAKNESS AND EFFECT IN THE BRAIN AND SPINAL CORD SYNDROMES	19
Market Drivers	19
ADDITIONAL DRIVERS FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS DRUG MARKET	20
FACTORS GOVERNING THE MARKET	20
COLLABORATIONS, MERGERS AND ACQUISITIONS	21
CHAPTER 3 ANTIFUNGAL DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (REPORT PHM029D)	24
INTRODUCTION	24
STUDY GOALS AND OBJECTIVES	24
REASONS FOR DOING THIS STUDY	24
INTENDED AUDIENCE	25
SCOPE OF REPORT	25
METHODOLOGY	25
INFORMATION SOURCES	25
ANALYST CREDENTIALS	26
RELATED BCC REPORTS	26
SUMMARY	26
<i>TABLE 5 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL THERAPEUTICS BY GEOGRAPHIC REGION, THROUGH 2016 (\$ MILLIONS)</i>	27
<i>FIGURE 4 GLOBAL SALES OF HUMAN ANTIFUNGALS, 2011 AND 2016 (\$ MILLIONS)</i>	27
OVERVIEW	27
HISTORY AND CURRENT STATE OF ANTIFUNGALS	28
TYPES OF PATHOGENIC FUNGI	28
DEFINITION OF THE INDUSTRY	29
INDUSTRY CONCEPTS	29
IMPORTANCE OF THE INDUSTRY	29
PRODUCT LIFE CYCLES	30
<i>TABLE 6 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG</i>	31
DEVELOPMENT OF ANTIFUNGALS	31
FDA-APPROVED ANTIFUNGALS	33
AZOLE ANTIFUNGALS	33

TOPIC	PAGE NO.
ECHINOCANDINS	33
POLYENES	33
ALLYLAMINES	33
MISCELLANEOUS ANTIFUNGALS	33
FUTURE DEVELOPMENTS	33
HUMAN CLINICAL DEVELOPMENT, 2009 TO 2011	34
NEW DRUG ACTIVITY	35
<i>TABLE 7 CLINICAL TRIALS OF ALL NEW DRUG THERAPIES AND COMBINATIONS BY ALL DATE FIELDS, 2009-2011</i>	35
<i>TABLE 8 SELECTED GLOBAL CLINICAL TRIALS OF ALL NEW DRUG THERAPIES THAT EITHER ARE COMPLETED OR ESTIMATED TO BE COMPLETED BETWEEN 2009 AND 2012</i>	35
ACTIVE OR COMPLETED STUDIES POSTED OR UPDATED, 2009 TO 2011	36
<i>TABLE 9 ACTIVE OR COMPLETED STUDIES, 2009-2011</i>	36
INTRODUCTION TO INDUSTRY APPLICATIONS OF ANTIFUNGAL MEDICINAL THERAPEUTICS	38
SCOPE OF APPLICATIONS: HUMAN HEALTHCARE	38
HUMAN FUNGAL INFECTIONS	39
Risk Factors for Developing Fungal Infections	40
<i>TABLE 10 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS</i>	41
CHAPTER 4 GLOBAL MARKETS FOR ASTHMA AND COPD DRUGS (REPORT PHM059B)	43
INTRODUCTION	43
STUDY GOALS AND OBJECTIVES	43
REASONS FOR DOING THE STUDY	43
SCOPE OF REPORT	43
METHODOLOGY	44
INTENDED AUDIENCE	44
INFORMATION SOURCES	44
ANALYST CREDENTIALS	45
RELATED BCC REPORTS	45
SUMMARY	45
<i>TABLE 11 GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	46
<i>FIGURE 5 GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY REGION, 2012 AND 2017 (%)</i>	46
OVERVIEW	47
PULMONARY DRUG DELIVERY	47
PULMONARY CONDITIONS AND THERAPIES	48
RESPIRATORY SYSTEM	48
LUNG	49
Particle Size, Toxicity and Drug Deposition	50
Systemic and Local Therapy	51
Pulmonary Drug Delivery-Devices	51
Device Characteristics	51
Manufacturing Techniques	53
ASTHMA	55
Symptoms of Asthma	56
Global Prevalence	56

TOPIC	PAGE NO.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	56
Symptoms of COPD	56
Medication Treatment	57
Types of Medication Treatments	57
Classification of Asthma and COPD Medications	57
Bronchodilators	57
Quick-acting Bronchodilators	57
Two Classes of Long-Term Bronchodilators	58
Anti-inflammatory Drugs	58
Combination Inhaled Corticosteroids and Long-acting Beta-2 Agonists (ICS/LABA)	58
Advantages of ICS/LABA	58
<i>TABLE 12 MARKETED ASTHMA AND COPD DRUG CLASSES</i>	59
Drug Delivery Methods	59
Inhaled Drugs	59
Metered-dose Inhaler	60
Pressurized MDI Devices	60
Types of Metered-dose Inhalers	60
Breath-activated Inhalers	60
Types of Breath-activated Inhalers	60
Dry Powder Inhalers	61
Disadvantages of DPI	61
Types of DPI Inhalers	61
Nebulizers	61
Usage	61
Types of Nebulized Drugs	62
Oral and Injectable Drugs	62
Oral Drug Types	62
Injectable Drug Types	62
ADVANTAGES/DISADVANTAGES OF DRUG DELIVERY METHODS	62
DRUG DEVELOPMENT PROCESS	62
DEVELOPMENT OF DISEASE-MODIFYING DRUGS	63
New Drug Targets	63
TECHNICAL ASPECTS IN THE DEVELOPMENT OF INHALED DRUGS	63
INTELLECTUAL PROPERTY RIGHTS	64
DRUG DEVELOPMENT	64
COMPLEX REGULATORY DRUG APPROVAL PROCESS	64
Approval Times	65
REGULATORY ISSUES	65
REMOVAL OF CFC-PROPELLED INHALERS	65
FDA DRUG SAFETY WARNINGS	65
INDUSTRY PLAYERS	66
TIERS OF COMPETITION	66
MAJOR DRUG MANUFACTURERS	67
GlaxoSmithKline	67
Merck	67
Boehringer Ingelheim	67
<i>TABLE 13 NET REVENUES FOR TOP SIX ASTHMA/COPD PRODUCT MANUFACTURERS, WITH PRODUCT(S), 2010 AND 2011 (\$ MILLIONS)</i>	67

TOPIC	PAGE NO.
SPECIALTY PHARMACEUTICAL COMPANIES	68
Teva Pharmaceutical	68
Chiesi Farmaceutici	68
Sunovion/Sepracor	68
<i>TABLE 14 NET REVENUES FOR TOP SPECIALTY ASTHMA/COPD MANUFACTURERS WITH PRODUCT(S), 2010 AND 2011 (\$ MILLIONS)</i>	69
SMALLER COMPANIES	69
<i>TABLE 15 NET REVENUES FOR SMALLER ASTHMA/COPD PRODUCT MANUFACTURER, WITH PRODUCT, 2010 AND 2011 (\$ MILLIONS)</i>	69
ACQUISITIONS AND MERGERS	69
<i>TABLE 16 ACQUISITIONS AND MERGERS IN THE ASTHMA AND COPD MARKET, JAN. 2008 TO JUNE 2012 (\$ MILLIONS)</i>	70
COMPETITIVE FACTORS	70
SIX COMPETITIVE FACTORS	70
Delivery Mode and Convenience	70
Product Efficacy and Dosage Frequency	71
Safety	71
Combination Drugs	72
Drug Pricing	72
Sales and Marketing	72
SIGNIFICANT TRENDS	72
GLOBAL AGING POPULATION LEADS TO INCREASING ASTHMA AND COPD PREVALENCE	73
NEW DRUG LAUNCHES OFFER ENHANCED TREATMENT OPTIONS	73
PATENT EXPIRATIONS OF MAJOR DRUGS AND GENERIC DRUG LAUNCHES WILL CHANGE THE MARKET	73
CHAPTER 5 GENITOURINARY DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (REPORT PHM115A)	76
INTRODUCTION	76
STUDY GOALS AND OBJECTIVES	76
REASONS FOR DOING THE STUDY	76
SCOPE OF REPORT	76
INTENDED AUDIENCE	77
METHODOLOGY AND INFORMATION SOURCES	78
ANALYST CREDENTIALS	78
RELATED BCC REPORTS	78
SUMMARY	78
<i>TABLE 17 MAJOR GENITOURINARY DRUG CATEGORIES REVENUE, THROUGH 2016 (\$ MILLIONS)*</i>	79
<i>FIGURE 6 MAJOR GENITOURINARY DRUG CATEGORIES REVENUE, 2009-2016 (\$ MILLIONS)*</i>	80
OVERVIEW	80
DISEASES OF THE GENITOURINARY SYSTEM	80
<i>TABLE 18 GENITOURINARY DISEASE NAMES, GENDER AND DESCRIPTION</i>	81
Benign Prostatic Hypertrophy (BPH)	81
Erectile Dysfunction (ED)	81
Incontinence (IC)	81
Overactive Bladder (OB)	82
Hormonal Contraception (HC)	82

TOPIC	PAGE NO.
Infertility (IF)	82
Infection (INF)	83
DRUGS GOING OFF-PATENT IN FORECAST PERIOD	83
<i>TABLE 19 GENITOURINARY DRUGS WITH EXPIRING PATENTS, 2010-2016</i>	83
REVENUE PROJECTION FOR GENITOURINARY DRUGS, 2011-2016	84
<i>TABLE 20 FIVE-YEAR PROJECTION FOR REVENUES IN GENITOURINARY DRUG MARKET, THROUGH 2016 (\$ MILLIONS)</i>	84
TOP 10 BEST-SELLING GENITOURINARY DRUGS, 2011	86
<i>TABLE 21 TOP 10 BEST-SELLING GENITOURINARY DRUGS IN 2011 (\$ MILLIONS/%)</i>	86
REVENUE BY GENITOURINARY DISEASE DRUG SEGMENT	86
<i>TABLE 22 REVENUES BY GENITOURINARY SEGMENT, 2011 (\$ MILLIONS/%)</i>	87
REVENUE FROM GENITOURINARY DRUGS BY GEOGRAPHIC AREA	87
<i>TABLE 23 REVENUE FROM GENITOURINARY DRUGS BY GEOGRAPHIC AREA, 2011 (\$ MILLIONS/%)</i>	87
MARKET OVERVIEW	88
MARKET SIZE AND FORECAST	89
<i>TABLE 24 REVENUE FROM GENITOURINARY DISEASE DRUGS FOR MAJOR COMPANIES, THROUGH 2016 (\$ MILLIONS)</i>	90
CHAPTER 6 GLOBAL MARKETS FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS (REPORT PHM117A)	93
INTRODUCTION	93
STUDY OBJECTIVES	93
REASONS FOR DOING THIS STUDY	93
CONTRIBUTIONS OF THE STUDY AND FOR WHOM	93
SCOPE OF THE STUDY	94
METHODOLOGY	94
INFORMATION SOURCES	94
ABOUT THE AUTHOR	94
RELATED BCC RESEARCH REPORTS	95
EXECUTIVE SUMMARY	95
<i>TABLE 25 GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017 (\$ MILLIONS)</i>	96
<i>FIGURE 7 GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017 (\$ MILLIONS)</i>	96
OVERVIEW	96
THE BRAIN	97
CEREBRAL CORTEX	97
BRAIN STEM	98
SPINAL CORD	99
NEUROTRANSMITTERS	100
CLASSIFICATION OF NEURODEGENERATIVE DISORDERS	100
<i>TABLE 26 CLASSIFICATION OF SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY PRIMARY CLINICAL/PATHOLOGICAL FEATURE</i>	101
NEURODEGENERATIVE DISORDERS	101
ALZHEIMER'S DISEASE	101
LEWY BODY DEMENTIA	102
PICK'S DISEASE	102
HUNTINGTON'S DISEASE	102

TOPIC	PAGE NO.
CORTICAL BASAL GANGLIONIC DEGENERATION	103
PARKINSON'S DISEASE	103
MULTIPLE SYSTEM ATROPHY	103
PROGRESSIVE SUPRANUCLEAR PALSY	103
HALLERVORDEN-SPATZ DISEASE	104
DIAGNOSTIC TESTS FOR NEURODEGENERATIVE DISORDERS	104
DIAGNOSTIC TESTS FOR PARKINSON'S	104
DIAGNOSTIC TESTS FOR ALZHEIMER'S	105
DIAGNOSTIC TESTS FOR PICK'S DISEASE	105
DIAGNOSTIC TESTS FOR MULTIPLE SYSTEM ATROPHY	105
DIAGNOSTIC TESTS FOR PROGRESSIVE SUPRANUCLEAR PALSY	106
DIAGNOSTIC TESTS FOR CORTICAL BASAL GANGLIONIC DEGENERATION	106
DIAGNOSTIC TESTS FOR LEWY BODY DEMENTIA	106
DIAGNOSTIC TESTS FOR HALLERVORDEN-SPATZ DISEASE	106
GLOBAL MARKETS	106
MARKETS BY CLINICAL/PATHOLOGICAL FEATURE	106
Market Overview	107
Market Revenues	108
<i>TABLE 27 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017 (\$ MILLIONS)</i>	108
<i>FIGURE 8 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017 (\$ MILLIONS)</i>	108
Market Share	109
<i>TABLE 28 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%)</i>	109
<i>FIGURE 9 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%)</i>	109
MARKET BY DISEASE TYPE	109
Market Overview	110
CURRENT SITUATION	111
MARKET TRENDS	112
SYNDROMES OF DEMENTIA	112
Market Drivers	113
MOVEMENT DISORDER SYNDROMES	113
Market Drivers	114
OVERALL DRIVERS OF THE MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS	115
OTHER FACTORS AFFECTING THE MARKET	115
COLLABORATIONS/MERGERS AND ACQUISITIONS	115

LIST OF TABLES

TABLE HEADING	PAGE NO.
TABLE 1 GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, THROUGH 2017 (\$ MILLIONS)	6
TABLE 2 CLASSIFICATION BY PRIMARY DYSFUNCTION	8
TABLE 3 GLOBAL REVENUES OF DRUG PRODUCTS FOR THE TREATMENT OF NEURODEGENERATIVE DYSFUNCTIONS, THROUGH 2017 (\$ MILLIONS)	14
TABLE 4 MARKET SHARE OF DRUGS USED FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS BY DYSFUNCTIONS, 2011 (%)	15
TABLE 5 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL THERAPEUTICS BY GEOGRAPHIC REGION, THROUGH 2016 (\$ MILLIONS)	27
TABLE 6 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG	31
TABLE 7 CLINICAL TRIALS OF ALL NEW DRUG THERAPIES AND COMBINATIONS BY ALL DATE FIELDS, 2009-2011	35
TABLE 8 SELECTED GLOBAL CLINICAL TRIALS OF ALL NEW DRUG THERAPIES THAT EITHER ARE COMPLETED OR ESTIMATED TO BE COMPLETED BETWEEN 2009 AND 2012	35
TABLE 9 ACTIVE OR COMPLETED STUDIES, 2009-2011	36
TABLE 10 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS	41
TABLE 11 GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE, THROUGH 2017 (\$ MILLIONS)	46
TABLE 12 MARKETED ASTHMA AND COPD DRUG CLASSES	59
TABLE 13 NET REVENUES FOR TOP SIX ASTHMA/COPD PRODUCT MANUFACTURERS, WITH PRODUCT(S), 2010 AND 2011 (\$ MILLIONS)	67
TABLE 14 NET REVENUES FOR TOP SPECIALTY ASTHMA/COPD MANUFACTURERS WITH PRODUCT(S), 2010 AND 2011 (\$ MILLIONS)	69
TABLE 15 NET REVENUES FOR SMALLER ASTHMA/COPD PRODUCT MANUFACTURER, WITH PRODUCT, 2010 AND 2011 (\$ MILLIONS)	69
TABLE 16 ACQUISITIONS AND MERGERS IN THE ASTHMA AND COPD MARKET, JAN. 2008 TO JUNE 2012 (\$ MILLIONS)	70
TABLE 17 MAJOR GENITOURINARY DRUG CATEGORIES REVENUE, THROUGH 2016 (\$ MILLIONS)*	79
TABLE 18 GENITOURINARY DISEASE NAMES, GENDER AND DESCRIPTION	81
TABLE 19 GENITOURINARY DRUGS WITH EXPIRING PATENTS, 2010-2016	83
TABLE 20 FIVE-YEAR PROJECTION FOR REVENUES IN GENITOURINARY DRUG MARKET, THROUGH 2016 (\$ MILLIONS)	84
TABLE 21 TOP 10 BEST-SELLING GENITOURINARY DRUGS IN 2011 (\$ MILLIONS/%)	86
TABLE 22 REVENUES BY GENITOURINARY SEGMENT, 2011 (\$ MILLIONS/%)	87
TABLE 23 REVENUE FROM GENITOURINARY DRUGS BY GEOGRAPHIC AREA, 2011 (\$ MILLIONS/%)	87
TABLE 24 REVENUE FROM GENITOURINARY DISEASE DRUGS FOR MAJOR COMPANIES, THROUGH 2016 (\$ MILLIONS)	90
TABLE 25 GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017 (\$ MILLIONS)	96
TABLE 26 CLASSIFICATION OF SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY PRIMARY CLINICAL/PATHOLOGICAL FEATURE	101
TABLE 27 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017 (\$ MILLIONS)	108
TABLE 28 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%)	109

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
FIGURE 1 GLOBAL MARKET FOR PROGRESSIVE ATAXIA AND WEAKNESS DISORDERS, 2010-2017 (\$ MILLIONS)	6
FIGURE 2 GLOBAL REVENUES OF DRUG PRODUCT FOR THE TREATMENT OF NEURODEGENERATIVE DYSFUNCTIONS, 2010-2017 (\$ MILLIONS)	14
FIGURE 3 MARKET SHARE OF DRUG USED FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS BY DYSFUNCTION, 2011 (%)	15
FIGURE 4 GLOBAL SALES OF HUMAN ANTIFUNGALS, 2011 AND 2016 (\$ MILLIONS)	27
FIGURE 5 GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY REGION, 2012 AND 2017 (%)	46
FIGURE 6 MAJOR GENITOURINARY DRUG CATEGORIES REVENUE, 2009-2016 (\$ MILLIONS)*	80
FIGURE 7 GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017 (\$ MILLIONS)	96
FIGURE 8 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017 (\$ MILLIONS)	108
FIGURE 9 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%)	109